Polycystic ovary syndrome (PCOS) is related to low levels of serum L-carnitine, which has antioxidant, antiinflammatory and antiapoptotic properties. The aim of this study was to investigate the effect of L-carnitine on folliculogenesis in mice following induction of PCOS. PCOS was induced by daily injections of testosterone enanthate (1 mg per 100 g, s.c., for 35 days). NMRI mice (21 days old) were divided into four groups (n ¼6 per group): Control, Control þ L-carnitine, PCOS and PCOS þL-carnitine. Mice were treated with 500 mg kg 1 , i.p., L-carnitine every second day for 28 days. Ovaries were studied stereologically and serum concentrations of FSH, LH, testosterone, interleukin (IL)6 and tumour necrosis factor (TNF)-a were determined using ELISA kits. Serum concentrations of malondialdehyde (MDA) and the ferric ion reducing antioxidant power (FRAP) were also analysed. Apoptosis of follicles was evaluated by terminal deoxyribonucleotidyl transferase-mediated dUTP–digoxigenin nick end-labelling (TUNEL). CD31 was assessed immunohistochemically. Data were analysed using one-way analysis of variance (ANOVA) and Tukey’s test, differences considered significant at P ,0.05.The total volume of the ovary, cortex volume, oocyte volume, zona pellucida thickness and the number of antral follicles increased significantly, whereas the number of primary and preantral follicles decreased significantly, in the PCOS þ L-carnitine versus PCOS group. In the PCOS þL-carnitine group, serum concentrations of FSH and FRAP increased significantly, whereas there were significant decreases in serum concentrations of testosterone, LH, MDA, IL-6 and TNF-a, as well as in the percentage of TUNEL-positive apoptotic cells, compared with the PCOS group. L-Carnitine improves folliculogenesis and is therefore suggested as a therapeutic supplement in the treatment of PCOS.
